Drug Trial Radar · NCT03744182
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 1, 2018
Primary completion
Mar 18, 2020
Study completion Mar 18, 2020
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
Conditions
- NAFLD
Interventions
HM15211Drug
A sterile solution of HM15211 contained in pre-filled syringes
Placebo of HM15211Drug
A sterile, matching solution in pre-filled syringes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: 12 weeks
- Incidence of Clinical Renal Function Lab AbnormalitiesTime frame: baseline and 12 weeks
- Vital SignsTime frame: baseline and 12 weeks
- 12-lead ECGTime frame: baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProSciento Inc.
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.